Journal of Affective Disorders
Volume 122, Issue 1 , Pages 39-45 , April 2010

Efficacy of ziprasidone in dysphoric mania: Pooled analysis of two double-blind studies

  • S. Stahl

      Affiliations

    • Department of Psychiatry, UCSD, San Diego, CA, USA
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, University of California-San Diego, 1930 Palomar Point Way, Carlsbad, CA 92008, USA. Tel.: +1 760 444 9903; fax: +1 760 931 8517.
    • ,
  • I. Lombardo

      Affiliations

    • Pfizer Inc., New York, NY, USA
    • ,
  • A. Loebel

      Affiliations

    • Pfizer Inc., New York, NY, USA
    • ,
  • F.S. Mandel

      Affiliations

    • Pfizer Inc., New York, NY, USA

Received 24 October 2008 ,Revised 11 June 2009 ,Accepted 15 June 2009.

References 

  1. Akiskal HS. The bipolar spectrum in psychiatric and general medical practice. Prim. Psychiatry. 2004;11(9):30–35
  2. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J. Affect. Disord. 2000;59(Suppl 1):S5–S30
  3. Angst J, Gamma A. Prevalence of bipolar disorders: traditional and novel approaches. Clin. Appr. Bipolar Disord. 2002;1:10–14
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Fourth ed.. Washington, DC: American Psychiatric Association; 1994;
  5. Azorin JM, Kaladjian A, Adida M, et al. Toward the delineation of mania subtypes in the French National EPIMAN-II Mille Cohort: comparisons with prior cluster analytic investigations. Eur. Arch. Psychiatry Clin. Neurosci. 2008;258(8):497–504
  6. Baker RW, Brown E, Akiskal HS, et al. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br. J. Psychiatry. 2004;185:472–478
  7. Benazzi F. Defining mixed depression. Prog. Neuropsychopharmacol. 2008;32:932–939
  8. Benazzi F. Reviewing the diagnostic validity and utility of mixed depression (depressive mixed states. Eur. Psychiatr. 2008;23:40–48
  9. Bowden CL, Collins MA, McElroy SL, et al. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology. 2005;30:1932–1939
  10. Cassidy F, Yatham LN, Berk M, Grof P. Pure and mixed manic subtypes: a review of diagnostic classification and validation. Bipolar Disord. 2008;10(1 Pt 2):131–143
  11. Clothier J, Swann AC, Freeman T. Dysphoric mania. J. Clin. Psychopharmacol. 1992;12:13S–16S
  12. Dilsaver SC, Chen YR, Shoaib AM, Swann AC. Phenomenology of mania: evidence for distinct depressed, dysphoric, and euphoric presentations. Am. J. Psychiatry. 1999;156(3):426–430
  13. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch. Gen. Psychiatry. 1978;35:837–844
  14. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 1976;33:766–771
  15. Endicott J, Cohen J, Nee J, Fleiss J, Sarantakos S. Hamilton Depression Rating Scale. Extracted from regular and change versions of the Schedule for Affective Disorders and Schizophrenia. Arch. Gen. Psychiatry. 1981;38:98–103
  16. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am. J. Psychiatry. 1992;149:108–111
  17. Frye MA, Altshuler LL, Szuba MP, Finch NN, Mintz J. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. J. Clin. Psychiatry. 1996;57:17–21
  18. Gonzalez-Pinto A, Tohen M, Lalaguna B, et al. Treatment of bipolar rapid cycling patients during dysphoric mania with olanzapine. J. Clin. Psychopharmacol. 2002;22:450–454
  19. Guy W. In: Early Clinical Drug Evaluation Manual. Washington, DC: United States Department of Health, Education, and Welfare; 1976;p. 217–222
  20. Hantouche EG, Akiskal HS, Azorin JM, Châtenet-Duchêne L, Lancrenon S. Clinical and psychometric characterization of depression in mixed mania: a report from the French National Cohort of 1090 manic patients. J. Affect. Disord. 2006;96:225–232
  21. Himmelhoch JM, Garfinkel ME. Sources of lithium resistance in mixed mania. Psychopharmacol. Bull. 1986;22:613–620
  22. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the U.S. population: re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 2003;73(1–2):123–131
  23. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry. 2002;59(6):530–537
  24. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int. J. Neuropsychopharmacol. 2003;6(2):127–137
  25. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry. 2003;60:261–269
  26. Judd LL, Schettler PJ, Solomon DA, Maser JD, Coryell W, Endicott J, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J. Affect. Disord. 2008;108(1–2):49–58
  27. Judd LL, Schettler PJ, Akiskal HS, Coryell W, Leon AC, Maser JD, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch. Gen. Psychiatry. 2008;65(4):386–394
  28. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  29. Keck PE, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry. 2003;160:741–748
  30. Krüger S, Trevor Young L, Bräunig P. Pharmacotherapy of bipolar mixed states. Bipolar Disord. 2005;7:205–215
  31. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat. 2001;11:9–21
  32. McElroy SL, Keck PE, Pope HG, Hudson JI, Faedda GL, Swann AC. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am. J. Psychiatry. 1992;149:1633–1644
  33. Potkin SG, Keck PE, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J. Clin. Psychopharmacol. 2005;25:301–310
  34. Prien RF, Himmelhoch JM, Kupfer DJ. Treatment of mixed mania. J. Affect. Disord. 1988;15:9–15
  35. Secunda SK, Katz MM, Swann A, et al. Mania: diagnosis, state measurement and prediction of treatment response. J. Affect. Disord. 1985;8:113–121
  36. Stahl SM. Stahls Essential Psychopharmacology. 3rd ed.. New York: Cambridge University Press; 2008;
  37. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry. 2003;64(Suppl 19):6–12
  38. Swann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch. Gen. Psychiatry. 1997;54:37–42
  39. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002;26:530–536
  40. Thuile J, Even C, Guelfi JD. Mixed states in bipolar disorders: a review of current therapeutic strategies. Encephale. 2005;31:617–623

PII: S0165-0327(09)00280-8

doi: 10.1016/j.jad.2009.06.023

Journal of Affective Disorders
Volume 122, Issue 1 , Pages 39-45 , April 2010

Article Tools

* Image Usage & Resolution